Background: Macrophages are important components of inflammatory processes in multiple sclerosis, closely linked to axonal loss, and can now be observed in vivo using ultra-small superparamagnetic iron oxide (USPIO). In the present 1-year longitudinal study, we aimed to determine the prevalence and the impact on tissue injury of macrophage infiltration in patients after the first clinical event of multiple sclerosis. Methods: Thirty-five patients, 32 years mean age, were imaged in a mean of 66 days after their first event using conventional magnetic resonance imaging, gadolinium (Gd) to probe blood-brain barrier integrity, USPIO to study macrophage infiltration and magnetization transfer ratio (MTR) to assess tissue structure integrity. Statistics were performed using two-group repeated-measures ANOVA. Any patient received treatment at baseline. Results: At baseline, patients showed 17 USPIO-positive lesions reflecting infiltration of macrophages present from the onset. This infiltration was associated with local higher loss of tissue structure as emphasized by significant lower MTR norm values (p<0.03) in USPIO + /Gd + lesions (n=16; MTR norm US-PIO + /Gd + =0.78 at baseline, MTR norm USPIO + /Gd + =0.81 at M12) relative to USPIO -/Gd + lesions (n=67; MTR norm USPIO -/Gd + =0.82 at baseline, MTR norm USPIO -/Gd + =0.85 at M12). No interaction in MTR values was observed during the 12 months follow-up (lesion type × time). Conclusion: Infiltration of activated macrophages evidenced by USPIO enhancement, is present at the onset of multiple sclerosis and is associated with higher and persistent local loss of tissue structure. Macrophage infiltration affects more tissue structure while tissue recovery during the following year has a similar pattern for USPIO and Gd-enhanced lesions, leading to relative higher persistent local loss of tissue structure in lesions showing USPIO enhancement at baseline.
Introduction
Macrophage infiltration is an important component of the inflammatory processes associated with multiple sclerosis (MS) . Several studies support a close relationship between macrophage infiltration and axonal loss. First, colocation of active macrophages and axonal injury has been reported. 1, 2 Secondly, macrophages synthesize free radicals and cytotoxic proteins 3 known to cause axonal loss 4, 5 through mitochondrial injury and subsequent energy failure. 6 Furthermore, axonal injury is a major substrate for permanent neurological disability in patients. 7, 8 Currently, the magnetic resonance imaging (MRI) marker of inflammation used in clinical routine is the T 1 -signal enhancement produced Ultra-small superparamagnetic iron oxide enhancement is associated with higher loss of brain tissue structure in clinically isolated syndrome by gadolinium chelate-based contrast agents. Gadolinium chelates passively cross the damaged blood-brain barrier (BBB), diffusing into the intercellular space. While gadolinium contrast agents are largely used in daily practice and allow the depiction of active inflammatory lesions, 9 they are markers of BBB disruption which are non-specific and non-exclusive, and are indirect markers of inflammatory cell infiltration. 10, 11 Recently, new contrast agents based on particles of ultrasmall superparamagnetic iron oxide (USPIO) have been proposed as new candidates for brain macrophage infiltration imaging. After intravenous injection, USPIO is internalized in the lymphatic system by circulating monocytes/macrophages cells, allowing the in vivo and non-invasive labelling of regions with macrophage infiltration. 12 Consequently, USPIO is mainly present in the newly infiltrated macrophages within the inflammatory lesions. 13 USPIO causes local decreases in longitudinal and transversal relaxation times leading to MRI contrast changes. This labelling has been shown to be specific to monocytes/macrophages in animal models 13, 14 and in humans. 15 Preliminary studies have proven the feasibility of using USPIO in patients with MS. [15] [16] [17] [18] These four studies have all initially focused on radiological pattern descriptions and spatial distributions of USPIO enhancements in relapsing-remitting MS (RRMS) and patients with progressive MS. They have shown that USPIO provides distinct and complementary information to gadolinium-enhanced MRI in line with pathological findings in experimental allergic encephalomyelitis 12, 13, 19 but also in other diseases involving macrophages infiltration such as cerebral ischemia. 20 These four MS studies have also suggested an association between USPIO enhancement patterns 15,17 and subsequent regional macroscopic loss of tissue structure demonstrated by the occurrence of chronic black holes. Thus, previous studies demonstrated discrepancies between the value of BBB integrity, shown by gadolinium enhancement, and macrophage infiltration, reflected by USPIO uptake, which seems to be more specific to investigate the subtle role of macrophages in the pathogenesis of MS, in line with their role in axonal loss and the neurodegenerative process.
In patients at the first stage of the disease, potential existence of USPIO enhancement and subsequent local tissue changes has never been investigated. One may suppose that in clinically isolated syndrome (CIS) suggestive of MS, the presence of USPIO enhancement may be associated with more destructive lesions sustained over time. To test this hypothesis, we performed a 1-year multi-centre prospective longitudinal study in patients with CIS using USPIO contrast imaging and multi-modal MRI.
Materials and methods

Patients and study design
Thirty-five patients (13 males, 22 females) were included in a prospective longitudinal study within 3 months after a first demyelinated clinical episode suggestive of MS. Patients were included after screening in five different French University hospitals (Rennes, Marseilles, Paris, Toulouse, Rheims) based on the following criteria: (i) age between 18 and 45; (ii) occurrence of the first presumed inflammatory demyelinating event in the central nervous system involving either the optic nerve, the spinal cord, a brain hemisphere, or the brainstem; (iii) no previous history of neurological symptoms suggestive of demyelination; (iv) no possible alternative diagnoses at the inclusion visit based on clinical examination and biological tests (lupus erythematous, antiphospholipid antibody syndrome, Behçet disease, sarcoidosis, Lyme's disease, cerebral arteritis, brain lymphoma, etc.); (v) patients fulfilling at least the dissemination in space criteria according to Polman et al. 2005; 21 ; (vi) Expanded Disability Status Scale (EDSS) between 0 and 5 at baseline; (vii) first infusion of USPIO within 3 months after the first clinical episode; (viii) no corticoids in the month before USPIO infusion and no previous administration of immunomodulatory or immunosuppressive drugs; (ix) no previous history of asthma, allergy, infusion of iron oxide particles within 5 months; (x) no pregnancy.
The local ethics committees approved the protocol and all subjects gave their informed written consent.
Patients' disability was rated using the Kurtzke EDSS at baseline and M12, on the day of the MRI exam.
Image acquisition
Patients were scanned with 3T commercially available MRI systems (Verio MR system Siemens, Erlangen Germany in Marseilles and Rennes and Achieva MR system Philips, Amsterdam, Netherlands in Rheims) at baseline and 12-months later (M12). Twenty-one patients were scanned on Verio systems (n=3 in Marseilles, n=18 in Rennes) and 14 patients were scanned on the Achieva system (n=14 in Rheims).
Conventional and quantitative MRI were acquired at baseline in two steps: before (day 1) and 24 hours after USPIO infusion (day 2). The first day, before USPIO infusion, the protocol included transverse fast spin-echo proton density-weighted and T2-weighted sequences (Verio: TR/TE 1 /TE 2 =6530/8.8/88ms and Achieva: TR/TE 1 /TE 2 =2269/8.2/90ms; all other parameters were the same: 44 contiguous sections, 3-mm section thickness, in-plane resolution 1 mm × 1 mm), 2D gradient-echo T2 * -weighted sequences (TR/ TE=50/27ms, 44 contiguous sections, 3-mm section thickness, Verio: in-plane resolution 1.3 mm × 1.3 mm and Achieva: 1 mm × 1 mm), transverse proton density-weighted spoiled gradient-echo sequences (Verio: TR/TE=750/4.5 ms and Achieva: TR/ TE=65.8/5.1 ms, all other parameters: 44 contiguous sections, 3-mm section thickness, in-plane resolution 1 mm × 1 mm) performed without (M 0 ) and with (M mt ) magnetization transfer (MT) saturation (Gaussian shape, 1.5 kHz off-water resonance, 500° for Verio, 620° for Achieva). Transverse spin-echo T 1 -weighted sequence (Verio: TR/TE=500/8.4 ms and Achieva: TR/TE=600/9.3 ms; all other parameters: 44 contiguous sections, 3-mm section thickness, in-plane resolution 1 mm × 1 mm) was also performed before and 5 min after intravenous administration of 0.1 mmol/kg of gadolinium (Gd) chelate (gadopentetate dimeglumine, Magnevist®, Bayer Schering Pharma, Berlin-Wedding) to identify lesions enhanced by gadolinum. After the first day MR exam at baseline, USPIO (SHU-555C; Bayer Schering Pharma, Berlin-Wedding) was injected once over approximately 30 min (40 µmol of iron/kg of body weight).
The second day MR exam at baseline (24 h after USPIO infusion) consisted of a transverse spin-echo T 1 -weighted sequence performed to identify lesions enhanced by USPIO.
For each patient, a follow-up MR exam was performed at M12 using the same protocol except for the infusion of USPIO.
Safety
Patients were monitored clinically after USPIO infusion and every 3 months by a neurologist experienced in clinical studies. All data were collected in case report forms, controlled by a clinical research assistant.
Image analysis
All conventional images were blindly analysed by three experts (JCF, IB, AT). The visual analysis consisted of post-gadolinium and post-USPIO T 1 -enhanced lesion count, according to the different patterns of USPIO enhancement previously described. 15 The overlap of USPIO and gadolinium enhancement was rated using a 3-point scale: <20%, 20-80% and >80% of the volume.
T2 lesions were delineated at baseline and M12 on the T2-weighted images by means of a semi-automated method 22 by the same experienced neurologist (AM).
Magnetization Transfer Ratio (MTR) maps were calculated on a voxel-by-voxel basis according to the following equation: MTR=((M 0 -M mt )/M 0 ), where M 0 and M mt were the images obtained respectively without and with the magnetization transfer saturation pulse (ImCalc tool, SPM12, Wellcome Trust Centre for Neuroimaging, London). Due to the multi-centric design of the study, one healthy control was scanned within a period of 2 months in each centre to obtain centre reference values of MTR (determined within the whole white matter). MTR values of all patients were expressed as ratios (MTR norm ) relative to the reference MTR recorded in the same control in each centre.
T2-weighted images and T2 lesions masks were coregistered onto the M mt images using the normalized mutual information procedure (SPM12). The coregistered masks of the T2 lesions were applied on the MTR maps to extract the MTR value of each lesion. At the end of the pipeline, we obtained MTR values of each lesion, classified according to the enhancement type. 23 
Statistical analysis
Differences of tissue structure expressed as MTR norm between USPIO + /Gd + and USPIO -/Gd + lesions at baseline and M12 were assessed using two-group repeated-measures ANOVA (p<0.05). This analysis allowed to test (i) for group effect (USPIO + /Gd + vs USPIO -/Gd + ), (ii) for time effect (baseline vs M12) and (iii) for (Time × Group) interaction.
Three-groups comparisons between patients who showed at least one USPIO enhancing lesion; in patients who showed only lesions enhanced by gadolinium and the patients who showed no enhanced lesions EDSS was compared using the Kruskall-Wallis test corrected for paired comparisons with the Steel-Dwass procedure (p<0.05).
The software used for this statistical assessment was JMP 9.0.0, SAS Institute Inc.
Results
Demographic and clinical characteristics of patients
Among the 35 patients included, four patients were lost to follow-up at M12. Considering the 31 patients followed in the study, their mean age at baseline was 32.1 (±SD=8.3) years. The mean period between the first inflammatory demyelinating event and the first MR exam was 66.3 (±21.7) days. No patients received any treatment at the onset and 14 patients out of the 31 followed patients received drug-modifying therapies between baseline and M12. No patients developed any adverse events due to USPIO infusion neither at baseline nor during the follow-up. All patients fulfilled 2005 McDonald criteria at 1 year; among them 13 converted to clinically definite MS. 21 Nine patients showed at least one USPIO-enhanced lesion and at least one gadolinium-enhanced lesion; 7 patients showed lesions enhanced only by gadolinium and 15 patients did not show any enhanced lesions.
There was no difference between these three groups in terms of age, sex, mean disease duration and baseline EDSS ( Table 1) .
Prevalence of USPIO and gadolinium enhancement
USPIO enhancement was hyperintense on T 1 -w images whereas no signal changes were observed in these lesions on T2*-w images.
In the whole group of followed patients, 16 USPIO + / Gd + enhanced lesions, 67 USPIO -/Gd + enhanced lesions were depicted. Only one lesion was USPIO + / Gdand converted to USPIO -/Gd + at M12. According to this marginal pattern, this lesion was not taken into account for the statistical analysis.
Among the 17 USPIO-positive lesions (16 USPIO + / Gd + and 1 USPIO + /Gd -) observed at baseline, three different patterns of USPIO enhancement were characterized: pattern 1 was lesions with a ring-like enhancement (n=4; seen in four patients), pattern 2 was lesions with a focal enhancement (n=3; seen in two patients) and pattern 3 was lesions returning to isointensity after USPIO infusion compared with the pre-contrast hypointense signal of the lesion (n=10; seen in seven patients) ( Figure 1 ).
For the 16 USPIO + /Gd + enhanced lesions, overlaps of USPIO and Gd enhancements were less than 20% for three lesions and between 20% and 80% for 13 lesions. No overlap greater than 80% was observed.
The enhanced lesions (n=83) at baseline (16 USPIO + / Gd + and 67 USPIO -/Gd + ) did not show any enhancement at M12.
Relationships between regional USPIO/ gadolinium enhancement and lesional tissue structure assessed by MTR
The two-group repeated-measures ANOVA comparing MTR norm values of USPIO + /Gd + and USPIO -/Gd + lesions at baseline and M12 showed a significant global effect (F=4.58, p=0.03). A significant group effect (p<0.03) was observed showing lower MTR values in USPIO + /Gd + lesions (n=16; MTR norm USPIO + / Gd + =0.78 at baseline and MTR norm USPIO + /Gd + =0.81 Table 1 . Demographic and clinical characteristics of patients. 
Patients with at least one USPIO-enhanced lesion (n=9)
Patients with only gadolinium-enhanced lesion(s) (n=7)
Discussion
This study demonstrates that infiltration of activated macrophages, highlighted by USPIO enhancement, is already present at the onset of MS and is associated with higher and persistent loss of tissue structure.
USPIO enhancement reflects active migration of macrophages across the BBB after USPIO phagocytosis in peripheral circulation by activated macrophages, especially in the lymph nodes and the spleen. 15, 24, 25 Nonetheless, Oude Engberink et al. showed that an early passage of "free" USPIO particles through the injured BBB can also occur in less than 1 hour after USPIO infusion, 26 but probably in a minor proportion and followed in a few hours by phagocytosis brought on by activated macrophages already present in the central nervous system. Thus, when patients were scanned at 24 h after infusion, USPIO particles were trapped in the phagosome of activated macrophages, in the majority of cases coming from the peripheral circulation and few already present in the acute demyelinated lesion. The present study evidenced, for the first time, an infiltration of activated macrophages in CIS. Surprisingly, the proportion of USPIO-positive lesions among the inflammatory active lesions appears lower compared with the previous studies performed in more advanced stages of the disease (RRMS). [15] [16] [17] This finding could be related to a lower macrophage activity in CIS compared with RRMS. In addition, whatever the stage of the disease, the delay between the last clinical attack and USPIO infusion may influence the proportion of USPIO-positive lesions, explaining the higher level of USPIO lesions in the previous studies that included only patients during an active phase of the disease. [15] [16] [17] The possibility that USPIO precedes gadolinium enhancement seems to be unlikely. Although the design of this study is not suitable for unequivocally answering this issue, the fact that the tissue structure of USPIO-enhanced lesions is different from gadolinium-enhanced lesions, even at distance of enhancement (at 1 year), argues that USPIO enhancement provides additional information and is not a common pattern of all lesions. These findings were also suggested by Tourdias et al., who showed that lesions enhanced by both contrast agents trended to become chronic black holes. 17 Moreover, based on monthly MRI scan, Vellinga et al. showed that only 4% of USPIO + /Gdlesions became Gd + in the follow-up. 15 Finally, in the present study, the lesion that was enhanced only by USPIO at baseline was enhanced by gadolinium 1 year later. This long time between the two enhancements suggests more a reactivation of this lesion that the same acute phase of demyelination.
The three patterns of USPIO enhancement previously described were observed in the present study. Among them, the "return to isointensity of a pre-contrast hypointense lesion" pattern is unconventional and the role of a technical issue such as slice positioning may be considered. Nevertheless, considering the frequency of this pattern, the cautious taken to acquire images (along the anterior-posterior commissure with contiguous 3 mm thickness slices covering the whole brain) and its absence with gadolinium argue for the relevancy of this pattern. We found that USPIO uptake was mainly depicted at the periphery of MS lesions (in the case of ring-like enhancement) and never completely overlapped gadolinium-enhanced areas. USPIO enhancement may reflect the presence of active macrophages known to be located particularly at the periphery of acute MS lesions. 27 Therefore, USPIO enhancement underlies the high specificity of this contrast agent to reveal macrophage infiltration.
The main finding of our study is that tissue injury assessed by MTR imaging was more severe in lesions enhanced by USPIO compared with lesions enhanced by gadolinium. This difference remained present 1 year later while no more enhancements occurred, highlighting the fact that this persistent difference is related to a more severe loss of tissue structure than only increased water content within the lesions. This result is consistent with a previous study performed in an animal model showing a MTR decrease in USPIO-enhanced lesions. 19 In humans, the existence of a relationship between USPIO enhancement and higher tissue damage was reported in patients with more advanced MS, using the count of T 1 hypointense lesion commonly used as a measure of severe tissue damage. 17 The pathophysiological processes leading to more severe tissue injury in lesions marked by USPIO remain unknown. In particular, it is not clear if macrophage infiltration contributes directly to loss of tissue structure or only reflects the involvement of these inflammatory cells in the phagocytosis of myelin and cellular fragments. Nevertheless, Trapp et al. previously showed that macrophages are abundantly present in active demyelinating lesions of patients with MS, frequently near terminal ovoids of transected axons. 8 Furthermore, the course of acute axonal injury correlates well with clinical severity in the experimental autoimmune encephalomyelitis model. 3 Interestingly, this acute axonal injury is seen only in areas that contain macrophages with profound cytoplasmic expression of inducible nitric oxide (NO) synthase and nitrotyrosin reactivity within the tissue. 3 Peripheral monocyte-derived macrophages produce high levels of NO in pathological conditions. 28 This production of NO affects axonal mitochondrial function, and the subsequent energy failure leads to activation of calcium-dependent proteases and axonal loss. 29 Thus, we hypothesize that macrophage infiltration participates directly in the loss of tissue structure.
While macrophages are present in all active lesions, only some of them are seen by USPIO enhancement.
Considering the multiple roles of macrophages in acute MS lesions, we can speculate that among them, only some, which were recently activated and brought into contact with USPIO, phagocytized these particles. A diffuse infra-visual USPIO uptake has been demonstrated using relaxometry technics. 18 Thus, to evidence visually this USPIO uptake, a high density of recently activated macrophages is needed. Furthermore, we can also speculate that USPIO enhancement is related to a specific lesion pattern, more likely to implicate a large number of activated macrophages, as described by Lucchinetti et al. 27 Interestingly, regardless of whether tissue structure at baseline was more damaged in the present study in the presence of macrophages marked by USPIO enhancement, local recovery of tissue structure during the following 12 months presented the same pattern of evolution within lesions showing USPIO or gadolinium enhancement. This finding suggests that the type of the initial inflammation process is the main predictor of tissue structure for the 12 months following the inflammatory episode. As discussed previously, we hypothesize that activated macrophage infiltration contributes directly to the loss of tissue structure. This loss mainly affects irreversibly small 4 and electrically active axons. 5 We can speculate that two main components explain the evidenced structural loss at baseline: an irreversible component of axonal loss, more important in USPIO-positive lesions because of the deleterious effects of activated macrophages, and a reversible component (due to oedema resorption and remyelination) which is the same whatever the enhancement type of lesion, explaining the same decay over time of tissue structure.
In the present study, it is notable that, in contrast with animal studies, visual analysis did not demonstrate any added value of T2*-w images compared with T 1 -w images to depict USPIO enhancement, as also reported by Vellinga et al., who have used the same SHU555C-USPIO. 15 This discrepancy may be due to the higher magnetic field and higher concentration of USPIO in animal studies. 15 Furthermore, a decrease of intensity in T2*-w images in some lesions enhanced by Sinerem-USPIO was reported in patients, 16 which supposes that it also depends on the properties of the USPIO particles used. A more precise future analysis, based on T2* relaxation times, can bring insights to the existence of subtle T2* modification with the present USPIO.
The present study allows demonstration of an unfavourable and sustained local effect on tissue structure when activated macrophages are present in acute MS lesions. Although the relapse rate was higher in patients with at least one USPIO-enhanced lesion, patients did not show EDSS progression, whatever the enhancement status, during this relatively shortterm follow-up. This clinical stability can be explained by compensatory mechanisms known to occur from the early stage of the disease. 30 Added to the limited number of patients showing USPIO enhancement, these two issues constitute the main limitations of the present study, avoiding the extrapolation of USPIO enhancement value to the daily clinical management and prognosis of patients. To test the prognosis value of USPIO and even more macrophage infiltration on clinical outcome of patients with CIS, further studies with a more substantial sample size and a longer follow-up are required. Finally, despite widespread distributions of USPIO and gadolinium-enhanced lesions through the brain, and the importance of MTR changes within lesions compared with normalappearing white matter, 31 the potential influence of regional variation of MTR values 32 on the results cannot be totally ruled out in the present study.
In conclusion, macrophage infiltration is present from the earliest stage of the disease and is associated with a major and persistent loss of tissue structure. The potential predictive value of USPIO enhancement in terms of future disability will be validated in further long-term studies.
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